Mpro/RdRp-IN-1 (Compound 1) is a dual-target inhibitor effective against SARS-CoV-2, targeting RdRp with an EC50 of 25.45 μM and Mpro with an IC50 of 125.4 μM. It exhibits an EC50 of 4.79 μM against HCoV-OC43 with a selectivity index (SI) of 10.89. Mpro/RdRp-IN-1 is used in SARS-CoV-2 infection research.